title: [Comparative studies on the immunoactive action of galactoside-specific mistletoe lectin. Pure substance compared to the standardized extract].
abstract: Comparative Studies on the Immunoactive Potency of Galactoside-specific Lectin from Mistletoe/Pure substance against standardized extract. Cellular and humoral aspects of the immunomodulating activity of the galactoside-specific lectin from mistletoe (ML-1) were investigated in cancer patients suffering from mammary carcinoma and compared to the immunoactive potency of a proprietary mistletoe extract standardized for ML-1 (ML-1 stand., Eurixor). Regular subcutaneous injections of the optimal dose of ML-1 and ML-1 stand. (1 ng/kg body weight; twice a week; for 4 weeks) yielded statistically significant increases of certain lymphocyte subsets (helper T-lymphocytes, natural killer (NK)-cells) which are generally believed to be involved in antitumor activity. Moreover, administration of either ML-1 preparation resulted in enhanced expression of interleukin (Il)-2 receptors on lymphatic cells and significantly increased serum levels of defined acute phase reactants (c-reactive protein, haptoglobin, C3 complement) as indicator of cellular and humoral activity. In vitro, exposition of human lymphocytes to ML-1 and ML-1 stand. resulted in enhanced expression of Il-2 receptors, which substantiated the capacity of both ML-1 preparations to affect immunological parameters within the host defense system. The effects of ML-1 and ML-1 stand. were comparable.
authors.affiliation: Institut für Medizinische Mikrobiologie und Hygiene, Universität zu Köln.
authors.forename: J
authors.initials: J
authors.lastname: Beuth
authors.forename: H L
authors.initials: HL
authors.lastname: Ko
authors.forename: L
authors.initials: L
authors.lastname: Tunggal
authors.forename: J
authors.initials: J
authors.lastname: Geisel
authors.forename: G
authors.initials: G
authors.lastname: Pulverer
mesh_terms: D000209:Acute-Phase Proteins / Q000378:metabolism; D000276:Adjuvants, Immunologic / Q000494:pharmacology*; D000917:Antibody Formation / Q000187:drug effects*; D001943:Breast Neoplasms / Q000276:immunology; D005260:Female; D005697:Galactosides / Q000037:antagonists & inhibitors*; D006801:Humans; D007111:Immunity, Cellular / Q000187:drug effects*; D066298:In Vitro Techniques; D007694:Killer Cells, Natural / Q000187:drug effects / Q000276:immunology; D037102:Lectins / Q000494:pharmacology*; D016131:Lymphocyte Subsets / Q000187:drug effects; D010936:Plant Extracts / Q000494:pharmacology*; D013601:T-Lymphocytes / Q000187:drug effects / Q000276:immunology
chemical_list: D000209:Acute-Phase Proteins; D000276:Adjuvants, Immunologic; D005697:Galactosides; D037102:Lectins; D010936:Plant Extracts